ED95 of remimazolam for loss of consciousness when used with remifentanil in the elderly

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0011645

Enrollment

Registered

2026-02-24

Start date

2026-03-09

Completion date

Unknown

Last updated

2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Subjects are allocated to either the Control group (Normal Saline) or the Remifentanil group (Remifentanil effect-site concentration 2.0 ng/ml). Remimazolam is then administered for anesthesia

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 65 to 85 years (inclusive) American Society of Anesthesiologists (ASA) physical status I or II Patients scheduled for elective surgery under general anesthesia Patients who understand the study and provide informed consent

Exclusion criteria

Exclusion criteria: Body Mass Index (BMI) > 30 kg/m² History of allergy or addiction to benzodiazepines or opioids Cognitive impairment Severe cardiac, renal, or hepatic disease

Design outcomes

Primary

Measure	Time frame
Loss of Consciousness (Defined as loss of eyelash reflex and verbal response)	—

Secondary

Measure	Time frame
Mean Arterial Pressure;Heart Rate;Oxygen Saturation;Bispectral Index	—

Countries

Korea, Republic of

Contacts

Public ContactTae Kwang Kim

Ajou University Hospital

itsagoodtimee@gmail.com+82-31-219-6434

Outcome results